Preliminary results of phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS) demonstrates rapid Gd-enhancing lesions decrease

Drug Category : Array
Conference Category : Array
Lead Author : Inglese M, et al.
Published Date : 26/10/2017
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/ECTRIMS%202017%20Inglese%20MRI.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top